琥珀酸脱氢酶复合物铁硫亚单位 B（SDHB）免疫组化在嗜铬细胞瘤、头颈部副神经节瘤、胸腹部副神经节瘤中的应用：在常规工作中使用它是否是一个好主意？

Succinate Dehydrogenase Complex Iron Sulfur Subunit B (SDHB) Immunohistochemistry in Pheochromocytoma, Head and Neck Paraganglioma, Thoraco-Abdomino-Pelvic Paragangliomas: Is It a Good Idea to Use in Routine Work?

机构信息

Health Sciences University, Kartal Lutfi Kirdar Research&Traning Hospital, Pathology Clinic, Istanbul, Turkey.

Pathology, Istınye University Medical Faculty, Turkey.

出版信息

Asian Pac J Cancer Prev. 2021 Jun 1;22(6):1721-1729. doi: 10.31557/APJCP.2021.22.6.1721.

DOI:10.31557/APJCP.2021.22.6.1721

PMID:34181326

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8418866/

Abstract

BACKGROUND

In this study, we aimed to detect Succinate Dehydrogenase Complex Iron Sulfur Subunit B (SDHB) frequency in paragangliomas and pheochromocytomas (PPGL) with immunohistochemistry; compare with Pheochromacytoma of the Adrenal Gland Scaled Score (PASS) classification and analyse the differences between pheochromocytoma (Pheo), head-neck paragangliomas (HNPGL) and thoraco-abdominal-pelvic paraganglioma (TAPPGL) sub-groups.

METHODS

A total 114 PPGL cases (73 HNPGL, 15 TAPPGL and 27 Pheo belonging to 112 cases) are included. Immunohistochemically, SDHB and Ki-67 are investigated and malignancy risks are determined by PASS classification. Results are assessed statistically with chi-square test and p <0,01 is considered significant.

RESULTS

SDHB mutations are observed in 20 of 114 (17.54 %) PPGL cases, 3 (11,12%) of which is Pheo, 12 (16,44) is HNPGL, and 5 (35,71%) is TAPPGL (P <0,02). While 15/82 (18,29%) cases with SDHB mutations do not have a malignancy potential according to PASS classification, 5/32 (15,63%) cases has (p=0,73). TAPPGL, HNPGL and Pheo sub-groups have a significant difference between SDHB expression (p <0,02), malignancy potential according to PASS classification (p <0,0001) and Ki-67 proliferation index (p <0,0001).

CONCLUSION

To identify patients for molecular pathological examination, routine application of SDHB immunohistochemistry to PPGL tumors are suggested especially in HNPGLs.

摘要

背景

在这项研究中，我们旨在通过免疫组织化学检测嗜铬细胞瘤和副神经节瘤（PPGL）中琥珀酸脱氢酶复合物铁硫亚基 B（SDHB）的频率；与肾上腺嗜铬细胞瘤的评分（PASS）分类进行比较，并分析嗜铬细胞瘤（Pheo）、头颈部副神经节瘤（HNPGL）和胸腹部-盆腔副神经节瘤（TAPPGL）亚组之间的差异。

方法

共纳入 114 例 PPGL 病例（73 例 HNPGL、15 例 TAPPGL 和 27 例 Pheo 来自 112 例患者）。通过免疫组织化学检测 SDHB 和 Ki-67，并通过 PASS 分类确定恶性风险。使用卡方检验进行统计学评估，p<0.01 认为具有统计学意义。

结果

在 114 例 PPGL 病例中观察到 20 例（17.54%）存在 SDHB 突变，其中 3 例（11.12%）为 Pheo，12 例（16.44%）为 HNPGL，5 例（35.71%）为 TAPPGL（p<0.02）。然而，根据 PASS 分类，有 15/82（18.29%）例 SDHB 突变的病例没有恶性潜能，但有 5/32（15.63%）例存在（p=0.73）。TAPPGL、HNPGL 和 Pheo 亚组在 SDHB 表达（p<0.02）、根据 PASS 分类的恶性潜能（p<0.0001）和 Ki-67 增殖指数（p<0.0001）方面存在显著差异。